Waeber B, Brunner H R
Presse Med. 1996 Oct 26;25(32):1533-5.
Angiotensin II antagonists are a promising new class of antihypertensive agents. Unlike angiotensin converting enzyme inhibitors, these new agents block the renin-angiotensin system by acting directly on the angiotensin II receptor. It is quite probable that these agents will become a first line therapeutic choice for hypertensive patients. Current clinical trials on primary prevention may confirm the indications for this new therapeutic class in a near feature.
血管紧张素II拮抗剂是一类很有前景的新型抗高血压药物。与血管紧张素转换酶抑制剂不同，这些新型药物通过直接作用于血管紧张素II受体来阻断肾素-血管紧张素系统。这些药物很有可能会成为高血压患者的一线治疗选择。目前关于一级预防的临床试验可能会在不久后证实这一新型治疗药物的适应证。
